The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis
Abstract
IMPORTANCE: The association of nonmotor features and Parkinson disease (PD) is increasingly recognized. Evidence suggests that inflammation may play a role in PD pathologic features and symptoms. OBJECTIVE: To quantitatively summarize the peripheral inflammatory cytokine data available for patients with PD. DATA SOURCE: A systematic search of peer-reviewed English-language articles from PubMed, PsycINFO, and the Cochrane Library without year limitation was performed from December 7, 2015, to March 23, 2016. The search terms included inflammation or cytokine or chemokine or tumor necrosis factor or interleukin or interferon or C-reactive protein AND Parkinson disease. STUDY SELECTION: Studies were included if they provided data on peripheral blood cytokine concentrations in patients with PD and a healthy control group. Studies were excluded if they contained in vitro analysis of stimulated or unstimulated levels of cytokines, samples that overlapped with other studies, patients not diagnosed with PD at blood sampling, or if the cytokine analyzed was assessed in fewer than 3 studies. DATA EXTRACTION AND SYNTHESIS: Data were extracted from the 25 included studies encompassing 1547 unique patients with PD and 1107 unique controls by 2 independent investigators. Data were pooled using a random-effects model with the Comprehensive Meta-analysis software. Effect sizes were generated as standardized mean differences of cytokine concentrations between patients with PD and healthy controls and converted to the Hedges g statistic. MAIN OUTCOMES AND MEASURES: Blood cytokine concentrations in patients with PD compared with controls. Aberrations in peripheral cytokine levels were hypothesized to be related to PD. RESULTS: Among the 2654 study participants, concentrations of interleukin 6 (IL-6) (Hedges g, 0.325; 95% CI, 0.007-0.643; P = .045) in 13 studies, tumor necrosis factor (Hedges g, 0.354; 95% CI, 0.144-0.563; P = .001) in 9 studies, IL-1β (Hedges g, 0.382; 95% CI, 0.142-0.621; P = .002) in 6 studies, C-reactive protein (Hedges g, 0.323; 95% CI, 0.052-0.593; P = .02) in 6 studies, IL-10 (Hedges g, 0.329; 95% CI, 0.051-0.607; P = .02) in 5 studies, RANTES (regulated on activation, normal T-expressed, and presumably secreted) (Hedges g, 0.605; 95% CI, 0.111-1.099; P = .02) in 5 studies, and IL-2 (Hedges g, 0.789; 95% CI, 0.105-1.472; P = .02) in 3 studies were significantly higher in patients with PD compared with healthy controls. No differences were found between patients with PD and healthy controls for concentrations of interferon-γ (Hedges g, 0.745; 95% CI, -0.192 to 1.682; P = .12) in 5 studies, IL-4 (Hedges g, 0.031; 95% CI, -0.191 to 0.253; P = .79) in 3 studies, and IL-8 (Hedges g, 0.072; 95% CI, -0.136 to 0.279; P = .50) in 3 studies. CONCLUSIONS AND RELEVANCE: The findings of the meta-analysis demonstrated higher peripheral concentrations of IL-6, tumor necrosis factor, IL-1β, IL-2, IL-10, C-reactive protein, and RANTES in patients with PD, strengthening the clinical evidence that PD is accompanied by an inflammatory response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Statistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · cited 1×
“The following exclusion criteria were applied: (1) in vitro studies that reported stimulated or unstimulated levels of cytokines; (2) samples overlapped with other studies; (3) patients were not diagnosed with PD at the time of blood sampling; and (4) the cytokine analyzed was assessed in fewer than 3 studies.”
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Quantitative Synthesis in Systematic Reviews
Lau, J., Ioannidis, J. P. A., & Schmid, C. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-9-199711010-00008 · Cited by 2,517
Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G. T., Counsell, C., Giladi, N., Holloway, R. G., Moore, C. G., Wenning, G. K., et al. (2004) · Movement Disorders · doi:10.1002/mds.20213 · Cited by 2,347
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
The Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742
A Meta-Analysis of Cytokines in Alzheimer's Disease
Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.012 · Cited by 1,108
Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Tabas, I., & Glass, C. K. (2013) · Science · doi:10.1126/science.1230720 · Cited by 1,093
Interleukin‐10: new perspectives on an old cytokine
Mosser, D. M., & Zhang, X. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00706.x · Cited by 1,077
Interleukin-1 and neuronal injury
Allan, S. M., Tyrrell, P. J., & Rothwell, N. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1664 · Cited by 992
Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90746-3 · Cited by 986
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855
Microglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 843
Blood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
Systematic evaluation of rating scales for impairment and disability in Parkinson's disease
Ramaker, C., Marinus, J., Stiggelbout, A. M., & van Hilten, B. J. (2002) · Movement Disorders · doi:10.1002/mds.10248 · Cited by 666
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 634
Self-citationInflammation as a causative factor in the aetiology of Parkinson's disease
Whitton, P. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707167 · Cited by 624
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease
Boka, G., Anglade, P., Wallach, D., Javoy-Agid, F., Agid, Y., & Hirsch, E. C. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90684-x · Cited by 590
Mogi, M., Harada, M., Narabayashi, H., Inagaki, H., Minami, M., & Nagatsu, T. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12706-3 · Cited by 545
Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis
Masi, A., Quintana, D. S., Glozier, N., Lloyd, A. R., Hickie, I. B., & Guastella, A. J. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.59 · Cited by 466
Sriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., & O'Callaghan, J. P. (2002) · The FASEB Journal · doi:10.1096/fj.02-0216fje · Cited by 362
McCoy, M. K., Martinez, T. N., Ruhn, K. A., Szymkowski, D. E., Smith, C. G., Botterman, B. R., Tansey, K. E., & Tansey, M. G. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1504-06.2006 · Cited by 354
Association of circulating TNF-α and IL-6 with ageing and parkinsonism
Dobbs, R. J., Charlett, A., Purkiss, A. G., Dobbs, S. M., Weller, C., & Peterson, D. W. (1999) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1999.tb00721.x · Cited by 324
Use of ibuprofen and risk of Parkinson disease
Gao, X., Chen, H., Schwarzschild, M. A., & Ascherio, A. (2011) · Neurology · doi:10.1212/wnl.0b013e31820f2d79 · Cited by 321
Brodacki, B., Staszewski, J., Toczyłowska, B., Kozłowska, E., Drela, N., Chalimoniuk, M., & Stępien, A. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.06.040 · Cited by 316
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE‐PD)
Williams‐Gray, C. H., Wijeyekoon, R., Yarnall, A. J., Lawson, R. A., Breen, D. P., Evans, J. R., Cummins, G. A., Duncan, G. W., Khoo, T. K., Burn, D. J., et al. (2016) · Movement Disorders · doi:10.1002/mds.26563 · Cited by 304
Inflammation and Adaptive Immunity in Parkinson's Disease
Mosley, R. L., Hutter-Saunders, J. A., Stone, D. K., & Gendelman, H. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009381 · Cited by 247
Dursun, E., Gezen-Ak, D., Hanağası, H., Bilgiç, B., Lohmann, E., Ertan, S., Atasoy, İ. L., Alaylıoğlu, M., Araz, Ö. S., Önal, B., et al. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.04.014 · Cited by 237
Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047387 · Cited by 236
Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease
Wahner, A. D., Bronstein, J. M., Bordelon, Y. M., & Ritz, B. (2007) · Neurology · doi:10.1212/01.wnl.0000279519.99344.ad · Cited by 213
IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-γ when combined with IL-18
Cai, G., Kastelein, R. A., & Hunter, C. A. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199909)29:09<2658::aid-immu2658>3.0.co;2-g · Cited by 191
Scalzo, P., Kümmer, A., Cardoso, F., & Teixeira, A. L. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2009.10.062 · Cited by 175
The association between infectious burden and Parkinson's disease: A case-control study
Bu, X.-L., Wang, X., Xiang, Y., Shen, L.-L., Wang, Q.-H., Liu, Y.-H., Jiao, S.-S., Wang, Y.-R., Cao, H.-Y., Yi, X., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.05.015 · Cited by 169
Problems with long-term levodopa therapy for Parkinson's disease.
MARSDEN, C. D. (1994) · PubMed · Cited by 168
The role of inflammation in sporadic and familial Parkinson’s disease
Deleidi, M., & Gasser, T. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1352-y · Cited by 167
Inflammatory cytokines and NT-proCNP in Parkinson’s disease patients
Koziorowski, D., Tomasiuk, R., Szlufik, S., & Friedman, A. (2012) · Cytokine · doi:10.1016/j.cyto.2012.07.030 · Cited by 165
Akıl, E., Bulut, A., Kaplan, İ., Özdemir, H. H., Arslan, D., & Aluçlu, M. U. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1976-1 · Cited by 163
Feng, Z.-H., Wang, T.-G., Li, D.-D., Fung, P., Wilson, B. C., Liu, B., Ali, S. F., Langenbach, R., & Hong, J.-S. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00704-8 · Cited by 160
Stypuła, G., Radek, M., Stepien, H., Żylińska, K., & Pawlikowski, M. (1996) · NeuroImmunoModulation · doi:10.1159/000097237 · Cited by 134
Scalzo, P. L., Kümmer, A., Cardoso, F., & Teixeira, A. L. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.08.001 · Cited by 126
Interleukin-6 produces neuronal loss in developing cerebellar granule neuron cultures
Conroy, S. M., Nguyen, V., Quina, L. A., Blakely-Gonzales, P., Ur, C. L., Netzeband, J. G., Prieto, A. L., & Gruol, D. L. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.06.014 · Cited by 126
Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients
Rota, E., Bellone, G., Rocca, P., Bergamasco, B., Emanuelli, G., & Ferrero, P. (2006) · Neurological Sciences · doi:10.1007/s10072-006-0562-6 · Cited by 125
Bhimani, R. (2014) · Rehabilitation Research and Practice · doi:10.1155/2014/718527 · Cited by 125
Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease
Rentzos, M., Nikolaou, C., Andreadou, E., Paraskevas, G. P., Rombos, A., Zoga, M., Tsoutsou, A., Boufidou, F., Kapaki, E., & Vassilopoulos, D. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00894.x · Cited by 123
Circulating interleukin-10 and interleukin-12 in Parkinson’s disease
Rentzos, M., Nikolaou, C., Andreadou, E., Paraskevas, G. P., Rombos, A., Zoga, M., Tsoutsou, A., Boufidou, F., Kapaki, E., & Vassilopoulos, D. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01103.x · Cited by 114
Parkinson disease with REM sleep behavior disorder: Features, α-synuclein, and inflammation
Hu, Y., Yu, S., Zuo, L.-J., Cao, C.-J., Wang, F., Chen, Z.-J., Du, Y., Lian, T., Wang, Y., Chan, P., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001308 · Cited by 112
Self-citationInterleukin-6 Serum Levels in Patients with Parkinson’s Disease
Hofmann, K. W., Schuh, A. F. S., Saute, J., Townsend, R., Fricke, D., Leke, R., Souza, D. O., Portela, L. V., Chaves, M. L. F., & Rieder, C. R. M. (2009) · Neurochemical Research · doi:10.1007/s11064-009-9921-z · Cited by 98
Correlation between Serum RANTES Levels and the Severity of Parkinson’s Disease
Tang, P., Li, C., Li, X., Liu, Y., Liu, P., Hou, C., & Li, R. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/208408 · Cited by 96
Swanson, C. R., Berlyand, Y., Xie, S. X., Alcalay, R. N., Chahine, L. M., & Chen‐Plotkin, A. S. (2015) · Movement Disorders · doi:10.1002/mds.26290 · Cited by 94
Assessing Publication Bias in Meta-Analysis
Soeken, K. L., & Sripusanapan, A. (2003) · Nursing Research · doi:10.1097/00006199-200301000-00009 · Cited by 94
α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease
Pirttilä, T., Mehta, P. D., Frey, H., & Wísniewski, H. M. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90026-4 · Cited by 94
COPPADIS Study Group, Santos‐García, D., Mir, P., Cubo, E., Vela, L., Rodríguez-Oroz, M. C., Martí, M. J., Arbelo, J. M., Infante, J., Kulisevsky, J., et al. (2016) · BMC Neurology · doi:10.1186/s12883-016-0548-9 · Cited by 89
Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
Bonuccelli, U., Dotto, P. D., & Rascol, O. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70835-1 · Cited by 87
Choi, C., Jeong, J.-H., Jang, J. S., Choi, K., Lee, J., Kwon, J., Choi, K., Lee, J.-S., & Kang, S. W. (2008) · Journal of Clinical Neurology · doi:10.3988/jcn.2008.4.2.84 · Cited by 73
Rocha, N. P., Teixeira, A. L., Scalzo, P. L., Barbosa, I. G., de Sousa, M. S., Morato, I. B., Vieira, É. L. M., Christo, P. P., Palotás, A., & Reis, H. J. (2013) · Movement Disorders · doi:10.1002/mds.25752 · Cited by 67
Baseline C-Reactive Protein Levels and Life Prognosis in Parkinson Disease
Sawada, H., Oeda, T., Umemura, A., Tomita, S., Kohsaka, M., Park, K., Yamamoto, K., & Sugiyama, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134118 · Cited by 63
Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson’s disease
Andican, G., Konukoğlu, D., Bozluolçay, M., Bayülkem, K., Firtiına, S., & Burçak, G. (2012) · Acta Neurologica Belgica · doi:10.1007/s13760-012-0015-3 · Cited by 63
Venters, H., Dantzer, R., & Kelley, K. W. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05385.x · Cited by 62
Song, I., Kim, J., Chung, S., & Lee, K.-S. (2009) · European Neurology · doi:10.1159/000222780 · Cited by 49
Correlation between Protective Immunity to α-Synuclein Aggregates, Oxidative Stress and Inflammation
Алексеевна, Г. М., Yanamandra, K., Kucheryanu, V. G., Bocharova, O. R., Sherstnev, V. V., Morozova‐Roche, L. A., & Sewell, R. D. E. (2012) · NeuroImmunoModulation · doi:10.1159/000341400 · Cited by 44
Impaired Production of Plasma Interleukin-6 in Patients with Parkinson's Disease
Selikhova, M. V., Кушлинский, Н. Е., Lyubimova, N. V., & Gusev, E. I. (2002) · Bulletin of Experimental Biology and Medicine · doi:10.1023/a:1015120930920 · Cited by 39
Is Neuroinflammation Involved in the Development of Dementia in Patients with Parkinson's Disease?
Song, I., Kim, Y., Cho, H.-J., & Chung, S. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.0474 · Cited by 38
Gangemi, S., Basile, G., Merendino, R. A., Epifanio, A., Pasquale, G. D., Ferlazzo, B., Nicita-Mauro, V., & Morgante, L. (2003) · Mediators of Inflammation · doi:10.1080/09629350310001599701 · Cited by 37
An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes
Mahlknecht, P., Stemberger, S., Sprenger, F., Rainer, J., Hametner, E., Kirchmair, R., Grabmer, C., Scherfler, C., Wenning, G. K., Seppi, K., et al. (2012) · Proteome Science · doi:10.1186/1477-5956-10-71 · Cited by 31
Cited by
The pathogenesis of Parkinson's disease
Morris, H. R., Spillantini, M. G., Sue, C. M., & Williams-Gray, C. H. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01478-2 · Cited by 1,019
Aho, V. T. E., Houser, M. C., Pereira, P. A. B., Chang, J., Rudi, K., Paulin, L., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00427-6 · Cited by 435
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease
Williams, G. P., Schonhoff, A. M., Jurkuvenaite, A., Gallups, N. J., Standaert, D. G., & Harms, A. S. (2021) · Brain · doi:10.1093/brain/awab103 · Cited by 306
Chen, X., Hu, Y., Cao, Z., Liu, Q., & Cheng, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02122 · Cited by 288
Self-citation
Metadata
- Authors
- Qin, X.-Y., Zhang, S.-P., Cao, C., Loh, Y. P., & Cheng, Y.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-11-01
- Volume
- 73
- Issue
- 11
- Pages
- 1316
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2525903933
- Cited by
- 554
- References
- 72
- FWCI
- 18.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.